At a glance
- Vosoritide is an FDA-approved drug, marketed as Voxzogo (first approval: November 19, 2021).
- PubMed lists 133 publications mentioning it, including 7 randomized controlled trials and 5 animal-only studies.
- ClinicalTrials.gov lists 18 registered studies testing it (12 active).
- FDA's adverse event system (FAERS) holds 1,331 reports mentioning it; 369 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
| Application | Product | Status | First approval | Sponsor |
|---|---|---|---|---|
| NDA214938 | VOXZOGO | Approved, marketed | November 19, 2021 | BIOMARIN PHARM |
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Correspondence on "Real-world outcomes of vosoritide in achondroplasia: A systematic review and meta-analysis of multinational clinical evidence" by Albuquerque et al.
- Achondroplasia: Current Disease-Modifying Therapies and Genome Editing Strategies.
- Retinal Structural and Microvascular Findings During Novel NPR-B-Targeted Vosoritide Therapy in Children with Achondroplasia.
- Evaluation of sleep-related breathing disorders and polysomnography findings in pediatric patients with achondroplasia.
- Emerging NPR-B agonists for cartilage and bone: from CNP biology to translational compound design.
- Growth plate senescence, chondrocyte biology, and the growth hormone-insulin-like growth factor 1 axis in childhood growth.
- Early closure of cranial base synchondroses in infants with Vosoritide-treated achondroplasia.
- Consensus statement on the management of Achondroplasia in the Middle East.
- A Case of Inadvertent Overdose of Vosoritide Injection in a Three-Month-Old Infant With Achondroplasia.
- The Ethics of Growth-Promoting Pharmaceuticals for Achondroplasia.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 18
- Active
- 12
- With posted results
- 3
Conditions studied
Show 8 more studies
All 18 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 1,331
- Serious
- 369
- With death outcome
- 8
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
FDA prescribing information
Official US prescribing information. Dosing sections are intentionally not shown.
Source: DailyMed / openFDA
Change history
No changes since monitoring began on October 30, 2026.